BR112023015666A2 - Isoforma de ngf, seu uso no tratamento de patologias oculares e composição farmacêutica - Google Patents
Isoforma de ngf, seu uso no tratamento de patologias oculares e composição farmacêuticaInfo
- Publication number
- BR112023015666A2 BR112023015666A2 BR112023015666A BR112023015666A BR112023015666A2 BR 112023015666 A2 BR112023015666 A2 BR 112023015666A2 BR 112023015666 A BR112023015666 A BR 112023015666A BR 112023015666 A BR112023015666 A BR 112023015666A BR 112023015666 A2 BR112023015666 A2 BR 112023015666A2
- Authority
- BR
- Brazil
- Prior art keywords
- ngf
- treatment
- ocular pathologies
- pharmaceutical composition
- isoform
- Prior art date
Links
- 102000001708 Protein Isoforms Human genes 0.000 title abstract 3
- 108010029485 Protein Isoforms Proteins 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000008397 ocular pathology Effects 0.000 abstract 3
- 230000001627 detrimental effect Effects 0.000 abstract 1
- 230000000861 pro-apoptotic effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Prostheses (AREA)
Abstract
isoforma de ngf, seu uso no tratamento de patologias oculares e composição farmacêutica. a presente invenção refere-se ao campo de tratamento de patologias oculares através da administração de um ngf, que compreende mais de 50% em peso da isoforma de ngf de seq id no: 1. o dito ngf é particularmente útil no tratamento de patologias oculares onde o efeito de proliferação e sobrevida de ngf é desejado e onde o efeito pró-apoptótico de p75ntr é prejudicial.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21155393.8A EP4039269A1 (en) | 2021-02-05 | 2021-02-05 | Ngf isoform for use in the treatment of ocular pathologies |
| PCT/EP2022/052761 WO2022167607A1 (en) | 2021-02-05 | 2022-02-04 | Ngf isoform for use in the treatment of ocular pathologies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023015666A2 true BR112023015666A2 (pt) | 2024-03-12 |
Family
ID=74556703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023015666A BR112023015666A2 (pt) | 2021-02-05 | 2022-02-04 | Isoforma de ngf, seu uso no tratamento de patologias oculares e composição farmacêutica |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240091311A1 (pt) |
| EP (2) | EP4039269A1 (pt) |
| JP (1) | JP2024506007A (pt) |
| CN (1) | CN117202922A (pt) |
| AU (1) | AU2022216840A1 (pt) |
| BR (1) | BR112023015666A2 (pt) |
| CA (1) | CA3208784A1 (pt) |
| IL (1) | IL304596A (pt) |
| WO (1) | WO2022167607A1 (pt) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE257514T1 (de) | 1998-10-09 | 2004-01-15 | Scil Proteins Gmbh | Verfahren zur gewinnung von aktivem beta-ngf |
| ITRM20060367A1 (it) * | 2006-07-13 | 2008-01-14 | Lay Line Genomics Spa | Muteine del hngf usi terapeutici e composizioni farmaceutiche |
| PL2907521T3 (pl) | 2011-12-19 | 2018-04-30 | Wacker Chemie Ag | Nowe mutanty prongf i ich zastosowania w wytwarzaniu beta-ngf |
| AU2019343188A1 (en) * | 2018-09-21 | 2021-05-20 | Aufbau Medical Innovations Limited | Compositions and methods for glaucoma |
| WO2020138560A1 (ko) * | 2018-12-28 | 2020-07-02 | 경상대학교병원 | 백내장 예방 또는 치료용 약학적 조성물 및 건강기능식품 |
| MX2022002833A (es) * | 2019-09-17 | 2022-04-06 | Chiesi Farm Spa | Agente para usarse en el tratamiento o prevencion de trastornos oftalmicos. |
-
2021
- 2021-02-05 EP EP21155393.8A patent/EP4039269A1/en not_active Withdrawn
-
2022
- 2022-02-04 WO PCT/EP2022/052761 patent/WO2022167607A1/en active Application Filing
- 2022-02-04 AU AU2022216840A patent/AU2022216840A1/en active Pending
- 2022-02-04 EP EP22705749.4A patent/EP4288082A1/en active Pending
- 2022-02-04 BR BR112023015666A patent/BR112023015666A2/pt unknown
- 2022-02-04 CN CN202280012800.8A patent/CN117202922A/zh active Pending
- 2022-02-04 JP JP2023547342A patent/JP2024506007A/ja active Pending
- 2022-02-04 CA CA3208784A patent/CA3208784A1/en active Pending
- 2022-02-04 US US18/275,849 patent/US20240091311A1/en active Pending
-
2023
- 2023-07-19 IL IL304596A patent/IL304596A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL304596A (en) | 2023-09-01 |
| CN117202922A (zh) | 2023-12-08 |
| EP4288082A1 (en) | 2023-12-13 |
| WO2022167607A1 (en) | 2022-08-11 |
| CA3208784A1 (en) | 2022-08-11 |
| EP4039269A1 (en) | 2022-08-10 |
| AU2022216840A1 (en) | 2023-08-10 |
| JP2024506007A (ja) | 2024-02-08 |
| AU2022216840A9 (en) | 2024-07-11 |
| US20240091311A1 (en) | 2024-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xiong et al. | Epigallocatechin-3-gallate promotes healthy lifespan through mitohormesis during early-to-mid adulthood in Caenorhabditis elegans | |
| BR112021024686A2 (pt) | Produto de bolsa de nicotina | |
| Lugrin et al. | The sirtuin inhibitor cambinol impairs MAPK signaling, inhibits inflammatory and innate immune responses and protects from septic shock | |
| Xiong et al. | Virucidal activity of Moringa A from Moringa oleifera seeds against Influenza A Viruses by regulating TFEB | |
| CO2022011728A2 (es) | Composiciones y usos de glp-1 | |
| BR112019014985A8 (pt) | Composição estável de ingrediente ativo lipossolúvel, microcápsula e processo de preparação e uso da mesma | |
| BR112022001413A2 (pt) | Preparação de canabidiol, e, método para tratar uma modificação da doença em um paciente que sofre de síndrome de dravet | |
| BR112021019256A2 (pt) | Moduladores de receptor x4 de proteína g relacionado a mas e produtos e métodos relacionados | |
| ECSP055680A (es) | Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf) | |
| BR112017005841A2 (pt) | mistura de eteramina, processo para a produção de uma mistura de eteramina, e, uso de uma mistura de eteramina. | |
| CO2019007409A2 (es) | Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos | |
| BR112023000747A2 (pt) | Composições para o tratamento de obesidade | |
| Yang et al. | Combined treatment with bone marrow mesenchymal stem cells and methylprednisolone in paraquat-induced acute lung injury | |
| Lin et al. | Tanshinone IIA, a constituent of Danshen, inhibits the release of glutamate in rat cerebrocortical nerve terminals | |
| Zeng et al. | P2Y 13 receptor-mediated rapid increase in intracellular calcium induced by ADP in cultured dorsal spinal cord microglia | |
| BR112021024886A2 (pt) | Métodos de tratar a doença de fabry em pacientes com insuficiência renal | |
| Wang et al. | Crocetin potentiates neurite growth in hippocampal neurons and facilitates functional recovery in rats with spinal cord injury | |
| BR112022004925A2 (pt) | Composto, isômero do mesmo, solvato do mesmo, hidrato do mesmo ou sal farmaceuticamente aceitável do mesmo, método de preparação, uso do dito composto e composição farmacêutica | |
| BR112021017612A2 (pt) | Película geradora de aerossol | |
| BR112023015666A2 (pt) | Isoforma de ngf, seu uso no tratamento de patologias oculares e composição farmacêutica | |
| ECSP21037191A (es) | Pirazoles como moduladores de la hemoglobina | |
| BR112022016131A2 (pt) | Compostos para tratamento de infecção por coronavírus | |
| BR112022024840A2 (pt) | Combinação de alcaftadina e um corticosteroide | |
| BR112023019795A2 (pt) | Composições nasais compreendendo alcaftadina | |
| BR112023001121A2 (pt) | Cepa c de prevotella histicola como uma terapia oral para doenças inflamatórias |